CD34 and diabetes mellitus: The diabetes models showed that CD34 has the potential to be used as a biomarker for monitoring β-cell failure in the progression of diabetes, i.e., a strong linear and negative correlation exists between the loss of β-cells and increase of CD34 cells during disease progression.